4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0001628280-25-009076
Director sold 20,000 shares at an average $356.44 ($7,128,759)
- Director acquired 20,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BATE KENNETH Director | 2025-02-27 | Option exercise | +6,000 | $111.06 | $666,360 | 7,912 | D |
| BATE KENNETH Director | 2025-02-27 | Option exercise | +9,470 | $65.06 | $616,118 | 17,382 | D |
| BATE KENNETH Director | 2025-02-27 | Option exercise | +4,530 | $9.45 | $42,809 | 21,912 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −100 | $351.01 | $35,101 | 21,812 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −500 | $351.99 | $175,995 | 21,312 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −238 | $353.83 | $84,213 | 21,074 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −8,545 | $355.08 | $3,034,150 | 12,529 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −2,791 | $356.51 | $995,016 | 9,738 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −2,038 | $357.27 | $728,109 | 7,700 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −3,548 | $358.33 | $1,271,359 | 4,152 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −2,024 | $359.21 | $727,042 | 2,128 | D |
| BATE KENNETH Director | 2025-02-27 | Sale | −216 | $360.07 | $77,774 | 1,912 | D |
| Derivatives | |||||||
| BATE KENNETH Director | 2025-02-27 | Option exercise · Stock Option (Right to Buy) | −6,000 | 0 | D | ||
| BATE KENNETH Director | 2025-02-27 | Option exercise · Stock Option (Right to Buy) | −9,470 | 0 | D | ||
| BATE KENNETH Director | 2025-02-27 | Option exercise · Stock Option (Right to Buy) | −4,530 | 5,470 | D | ||
| Open-market sales · 20,000 sh · avg $356.44 · $7,128,759 | |||||||
Loading xslF345X05/wk-form4_1740778208.xml…